Fast Money 11/26/25

26 Nov 2025 · 44 min

Ask about this episode

Ask anything about it. ChatGPT or Claude reads this page and answers with the times it was said.

Connect VO and ask about every podcast you hear, including the moments you saved. Add to ChatGPT · Add to Claude

In short

Fast Money Podcast Episode Notes

Episode Title

Fast Money 11/26/25 Podcast Description Hosted by Melissa Lee and a panel of top traders, "Fast Money" delivers actionable news for investors, airing weeknights at 5 PM ET on CNBC.

---

Episode Summary In this episode, the traders discuss market trends leading into the Thanksgiving holiday, including the potential for a year-end rally, the impact of the Federal Reserve's decisions on interest rates, and various stock performances, especially in the pharmaceutical and technology sectors.

Key Themes

  1. Market Overview:
  2. Stocks rally heading into Thanksgiving with major indices showing gains.
  3. The VIX (fear index) has decreased, indicating lower market volatility.
  4. Positive sentiment surrounding potential Fed rate cuts, with a likelihood of cuts above 50% for December.
  1. Pharmaceutical Sector:
  2. Eli Lilly faces competition with a potential threat from Amgen's upcoming obesity drug data.
  3. Discussions about the valuation of Lilly in comparison to competitors like Merck and Bristol Myers.
  1. Technology Sector:
  2. Oracle's stock shows signs of recovery after a rough month, with analysts suggesting the company is undervalued despite recent challenges.
  3. Discussion on the fluctuating performance of big tech stocks, including NVIDIA and Alphabet.
  1. Crypto Concerns:
  2. Highlight of a recent $11 million Bitcoin heist, raising concerns about cryptocurrency security and impacting market sentiment.
  1. Travel Sector:
  2. Airlines prepare for a busy Thanksgiving travel period, with Delta Airlines highlighted as a strong performer amidst growing demand.

---

Detailed Notes

Market Trends and Federal Reserve Impact

  • Market Performance:
  • The S&P 500 has gained over 3% in the shortened trading week.
  • Declines in the 10-year Treasury yield signal investor confidence.
  • Fed Commentary:
  • Discussions of Fed officials hinting at potential rate cuts, leading to bullish sentiments in the markets.

Pharmaceuticals Under Scrutiny

  • Eli Lilly vs. Amgen:
  • Eli Lilly's stock has risen significantly, but potential data from Amgen's obesity drug could pressure shares downwards.
  • Market concerns regarding high valuations amid increasing competition.
  • Valuation Comparisons:
  • Eli Lilly trades at a premium (around 35 times next year's earnings) compared to Merck and Bristol Myers (around 11-12 times).
  • The discussion centers around the sustainability of these valuations in a competitive environment.

Technology Sector Dynamics

  • Oracle's Recovery:
  • Shares of Oracle rose by 4% after positive analyst ratings, suggesting it is undervalued based on its cloud business, particularly in AI.
  • NVIDIA Underperformance:
  • NVIDIA is not leading the market despite its historical dominance, as other tech stocks like Alphabet gain traction.

Crypto Security Issues

  • Bitcoin Heist Incident:
  • A significant robbery involving a tech investor highlights the security vulnerabilities in self-custody of digital assets.
  • Rise in "wrench attacks" as criminals exploit facial recognition technology to access funds.

Airline Stocks and Travel Forecast

  • Thanksgiving Travel:
  • AAA predicts 6 million travelers will fly domestically, a sign of recovery in the airline industry.
  • Delta Airlines is noted for its strong performance and revenue growth, suggesting a positive outlook heading into the holiday season.

---

Final Thoughts

  • The episode emphasizes a cautiously optimistic outlook for the markets as year-end rallies seem plausible with favorable economic indicators.
  • The discussions on different sectors provide insight into strategic investment opportunities based on market conditions and individual stock performances.
  • The episode wraps up with a reflection on the changing landscape of investment, particularly in technology and health sectors, amidst ongoing volatility.

---

Disclaimer All opinions expressed are those of the participants and do not reflect the opinions of CNBC or its affiliates. Investments discussed may not be suitable for all investors.

Written by AI. May contain mistakes. Listen to the episode to check what was said.

Hear the part that matters, and keep it.Open this episode in VO. Double tap your headphones to save a moment as you listen.
Get VO free

Transcript

Automatic transcript. May contain errors.

0:01Live from the Nasdaq market side in the heart of New York City's Times Square, this is Fast money. Here's what's on tap tonight. Thankful for gains. Stocks rallying into a shortened holiday week as markets head into Thanksgiving in the green. So with volatility and rates down and the Fed back in play, are we headed for an end of year holiday rally? We'll debate that. Plus, pharma red flag, the competition creeping up on Eli Lilly and how one biotech company's drug data could drag the pharma giant lower. And later, bounce back in Oracle after a rough month. how airline stocks are faring ahead of a busy holiday weekend, and the dark side of crypto, the$11 million Bitcoin heist making headlines, the potential impact on crypto pricing.

0:41I'm Melissa Lee coming to you live from Studio B at the NASDAQ. On the desk tonight, Steve Grasso, Guy Adami, Tim C. Warren, Mike Coe. We start off with Marcus heading into Thanksgiving stuffed with positive news. The major average is riding a four-day winning streak into the holiday. The S &P 500 up more than 3 % so far in this shortened trading week. The VIX, Wall Street's fear index, a far cry from last week's high, is now back below 18. The 10-year Treasury has dropped nearly 15 basis points in terms of yields in the last week, closing today just under 4%. And investors are once again betting there is now a really good chance the Fed will cut rates at the December meeting, odds swinging more than 50 % just from this time last week.

1:23So a seasonality on the horizon. This week's rebound. Do we think a year-long rally, year-end rally is coming? Guy. Gobble, gobble. I had to say that. Happy hump day. Let's get it out of our system now. OK, it's out. It's amazing. You know, Tim talked about this the other day. The fact that last week we were talking about, I was talking about the potential for an outside month to the downside when the S &P 500 was 6500 ish. We had made a new all time high in the month of November. We were flirting with the lows in October. They defended the 100 day moving average. And here we We are 250 or so handles higher.

1:59As a matter of fact, if something weird happens on Friday, you could have an outside month to the upside if we close on all-time highs. That's not out of the realm of possibility given what we're seeing. You mentioned the VIX getting tame again. It was absolutely showing warning signs a week or so ago. Yields coming down, even Bitcoin getting off the mat, all good things. And I got to tell you something, as we get into December, as bearish as I want to be, it's very hard given the calendar. You know, when you look at people and funds into year-end, And the reason why it's historically a positive sign or a positive seasonality for the market is if you're long the market, you want to see your stocks go higher.

2:35If you're underperforming the market, you want to average or you want to dress those positions up. So not saying that they're they're market manipulating, but you're more apt to buy this dip to make your existing positions look better than worse. So, you know, we always talk about the Fed and are they the biggest thing for the market? Well, did this week prove that? I think pretty much people are still worried about the Fed, right? So worried about Powell got a little more hawkish. That sent the market lower. And now we see a little more dovish and the market's higher. I think it's as simple as that.

3:10We had Waller on Monday telling another network that he would be inclined to cut rates. We have J.P. Morgan this afternoon flipping and now seeing a cut in December. Tim, so it does seem the Fed is a force in terms of Fed cut. Great for the markets. we are clear for that. There's a glide path forward. There's that glide path. And the Fed's always, of course. I mean, the fact that we're even, I don't think we're debating it. So let me just say, I thought it started last week, last Friday, and that's what turned the market was the Fed's Williams, New York Fed, arguably the most important Fed. And so you combine that with what was, it's a week, by the way that forgot NVIDIA.

3:52It's the week that NVIDIA forgot. And ultimately, the dynamic here is it's a great show for equities given that leadership coming from the semiconductors, which did lead, but not by NVIDIA, was there. So JP Morgan, the four mentioned, there they were upgrading their S &P to 7 ,500 next year, but they said it could actually be closer to 8 ,000 if we have a more dovish Fed. They qualified it and said we could go even higher. But at the root of they and other houses on Wall Street are the quality of earnings. And that really is, I think, part of the story here. This year-end rally and off of those lows, those intraday lows from last Friday, you've got almost a 10.5 % move in semis.

4:35You've got a almost 6 % move in the NASDAQ. Dare I utter the word small cap in the same sentence. And they rallied almost 8%. And so the question for investors often is during these bouts of volatility, should you you'd be doing anything or you should be buying. I'll just add one more thing is that retail showed both last Friday and on Monday. And this is actually data I got from JP Morgan, which is that they had one of their highest buying days, up days on Monday and 94 percentile up buying day on Monday after the kind of fallout from Friday. So I think retail is alive and well, and I think the market's going higher.

5:12And retail has largely been right all year. Michael, what do you see here going forward? Well, you brought up the VIX at the very beginning. Two things about that. The first is that we've seen multiple times this year that when the VIX has gotten north of 25, that that represented maybe a little bit of excess fear, a slightly oversold condition. And it seems like that was reiterated again very recently. The other thing about the VIX I would point out is that just because of the mechanics of how it is calculated, it looks 30 days in advance and is estimating the volatility that the S &P is going to experience over that intervening 30 days.

5:47But there would normally be what, 22 trading days in that session, in that period of time. Now we have slightly less because we've got a half day Friday, we're off tomorrow, and then we have a half day on Christmas Eve, and we're off on Christmas. So in that 30 day window, we're actually three days shy of the 22 you would normally experience. So the VIX is actually slightly higher, and it's on its way down. What does that tell me? I actually think there could be a little bit more room to the upside here because it seems like that oversold condition probably could run, you know, a little bit further from here.

6:18A little more to the upside, so more volatility potentially in these markets. I mean, what we've seen is something, I don't want to say extraordinary, but very interesting in terms of what has churned in this market. So we had Apple today, fresh all-time high, Alphabet coming off of all-time highs. And in the meantime, Tim mentioned the week that left behind NVIDIA, the week that left behind and Oracle. We're seeing this sort of rethink of AI, a rethink of AI spend, and therefore a rethink of who is leadership in big cap technology. Yeah, and if you had said to me, we play this game, if you had said to me, NVIDIA is going to be underperforming where the rest of these things, I'd be like, well, it's got to be dragging the rest of the market down with it, but it's not.

6:59I mean, the S &P has done this without NVIDIA. I mean, NVIDIA has been sort of meandering here at this sort of 180 level for quite some time. And quite frankly, it feels vulnerable to the downside, yet the broader market continues to grind higher. It's very impressive. And again, the fact that we traded down to those levels when we did and held it and defended it and it bounced the way we are, even I have to admit that's extraordinarily impressive. I felt that NVIDIA, you know, at 85 percent market share, it's a positive if that sells off and the others rally. The hyperscalers are creating their own chips.

7:33Not everyone needs the chip that NVIDIA creates. Some are basic needs. You have things that are just basically searching the web. You have things that really need inference. So I don't think that NVIDIA is on the top of the hill for long, but it's outlasted what I thought it would be able to run to. But how about from this point on? Yeah, I think the others do better than NVIDIA. I think Meta, Microsoft, the obvious ones do better. I think Amazon does better. So I think NVIDIA loses, they win. Oh, Mike, do you do you agree in terms of the churn within big cap technology, the reordering of the AI hierarchy, if you will?

8:14Well, I think it was a couple of weeks ago was my final trade. I mentioned Alphabet. We bought it on that dip the following Friday and we sold NVIDIA the day after earnings. You know, it's been a good run, but that was some relative weakness. It looks like that's not I mean, what are we down like one and a half, two percent from where we we sold it. But I agree with Steve that I think that you want to actually see it broaden out a little bit. And you don't need NVIDIA to carry the whole market by itself. I think that's kind of what this week illustrated. In terms of Apple, though, here we are sitting at all-time highs.

8:47Yeah, it's impressive. Money flows, I think, is a big part of it. You know, Tim has mentioned the fact that AI is probably not priced in. They seemingly, you know, maybe by being second or third, they're actually first in terms of the market rewarding them. It does make sense. Listen, I still think valuation is a problem. I get the install base and all those things, but you're really paying up here 32 times next year's numbers. Yep. For more on positioning your portfolio into year end, let's bring in Kathy Entwistle, Managing Director at Morgan Stanley Private Wealth Management. Kathy, great to have you here on set.

9:16Thanks. What are you telling clients? I mean, they call you right now and they're like, where are we in the markets? Because everything looks great. Absolutely. We're taking these opportunities where markets have volatility. Those are always opportunities for making changes, adding money in as markets are going down and also peeling off a little bit as they're rising. You're advocating or you're proposing to your clients that they sort of scale back on big cap technology. How is that message being received on the other end? Mostly, yeah, cautiously, but we're also we're scaling back. We're not we're not removing it.

9:49Right. We're just scaling back. So we're pulling back a little bit. But, you know, there were seven stocks in the S &P 500 that, like, you know, blew up the whole S &P 500, did great. 493 still remain. We think there's still opportunities in those other stocks as well. So we're trying to be more equal weighted, in a sense, and pull back on some of the overweights. What's changed, in your view, to move from an overweight to more of an equal weight on big cap technology? Just the fact that there's been such a run up, that there's been some issues with some of the companies not performing as well as they had been.

10:23And also that there's just more opportunity out there and we don't want to be concentrated. So, Kathy, when you look at it, I understand the diversification and the seven versus the 493. But those seven have actually earned all the revenues. Most of it. So how do you decide on where to diversify out of those seven? Are you looking small cap, which is unprofitable, in hopes that lower rates will help these companies? How do you decipher which ones you go to that have the revenue and the EPS tailwinds? Basically, the S &P 500, U.S. large cap, we like just very basic generic companies in a sense that we think have the opportunity to take the AI that's out in the markets and run with it.

11:05So we're not necessarily looking at all the AI companies. We're looking at which companies can run using AI and where we're going to get the most pop for our money there. I'll tell you, Kathy, both Tim and I are thinking of the great John Entwistle. I'm sure you've heard that before, but I had to mention it. With that said, private equity. I think you guys are trying to sort of get your clients involved. That's something new over the last couple of years. Can you speak to that? Yeah, absolutely. So we all remember the days of the big IPOs and a lot of the wealth creation happening at that IPO offering.

11:37Now we're finding that companies are staying private longer and the wealth creation is happening before a company goes public. So in that respect, we want our clients to participate in that growth and we are putting them in private markets. So it's not really private equity per se. It's private markets specifically. So potentially these unicorns that if they went public, they would be unicorns, but they're staying private longer. Like I don't know if it's open AI, but like an open AI. Right. Opportunities that where companies are staying private longer. to be able to participate in that growth.

12:09Also, when you think about infrastructure, we have private infrastructure, we have private equity, we have private credit. And private infrastructure, it used to be bridges, tunnels, roads. Now it's data centers and cell towers. So in that respect, you're getting access to maybe data centers that seem to be a very hot area to invest in right now, and you're getting easier access to it. How do you view the entire portfolio if you are trying to scale back on big tech exposure, but then you've got the exposure in private equity or private markets to data center? Absolutely. Well, it used to be a 60-40, 60 equity, 40 fixed income.

12:47That's not the case necessarily anymore. We're peeling back a little bit on the equity side. A lot of our clients have won the game. They don't need to take huge risks in the market. So we'll end up putting them, maybe get down to 55 % in equities, add the alternatives. And we still like fixed income. I heard someone earlier talking about maybe munis aren't working. We think munis are going to be really great first quarter next year. So get a little deeper on that risk curve. So what's the conversation like when you talk about crypto, whether it's specifically Bitcoin or how they're investing in it?

13:16Is it through ETFs? What modality are they using? Absolutely. We're using mostly ETFs. Clients are really curious and interested. I would say we're really at the beginning, the point of learning and understanding about crypto, at least our clients are. So we're trying to educate them, trying to have them dip their toe in the water. And ETFs seem to be the area where they're most comfortable stepping into that area right now. Kathy, great to see you. Thank you. Have a great Thanksgiving. Kathy Entwistle of Morgan Stanley. Mike Coe, what do you think about scaling back a little bit on big cap tech exposure?

13:53I think that's okay. I don't know that private credit would be the place that I would deploy that money, though. I actually think that there's probably a decent amount of risk in private credit, actually. I mean, I understand it's a fast-growing area, but I don't think, you know, these are not mark-to-market instruments. So that's something that I think I would caution people about if that's an area that they are contemplating right now. As far as fixed income is concerned, though, I think it can be in like the five to seven year tenors. And I think that actually the results are going to be reasonably attractive in that area.

14:27And I think there is a lid to where the rates are anyway. So that's going to be less duration. And we're probably not going to see those rates spike. So I think that's probably a good place to diversify. Private credit, private equity, unless you're a vulture investor, I'd probably stay away from those two areas. Tim? Well, I think you have a discussion about asset class allocation. And it also depends on just how high net worth the client is. What Kathy was talking about, some of those clients, ultra high net worths, for sure, they should be in alts and alts are non-correlated. And the question is, you know, what percentage of a portfolio should be in alts?

15:03I think the other question we've also digested over the last three to six months is what's going on with gold? Where is gold as an allocation? Where are precious metals? I think it's fascinating that really for the first time since they have been in institutional allocation, Bitcoin or crypto assets have had their first test and probably I wouldn't say they failed the test. I think it's been, again, a very interesting time to see how institutions have handled it. We've talked on this show how the fact that you now have it in institutional hands may mean it's in faster money, believe it or not, than some of the crypto hands.

15:37But fascinating conversation. Asset allocation for high net worth, ultra high net worth is different than it was. 60-40 is, I think, you know, it's not that it's outdated, but I do think it's yesterday's news. And I think you want to have as much tech today as you had yesterday. I agree with Tim real quick on the gold. To me, it's fascinating that the GDX did not sell off in a meaningful way. And if you look at it right now, it's still within sort of earshot of its all-time high, which I think is very encouraging. I think it speaks to the fact that people have not given up on the gold trade, nor should they.

16:10We've got breaking news we want to get to on the shooting in Washington, D.C. Eamon Javers has got some details here. Eamon. Melissa, authorities here in Washington just wrapped up a press conference giving some additional detail on that shooting that we saw here in Washington at just about 2.15 this afternoon, just a couple of blocks away from the White House. Most importantly, what authorities are saying is that the two National Guardsmen who were shot in the incident are alive. They are in critical condition. That contradicts the report that we had from the governor of West Virginia earlier, who said that both of those National Guardsmen had died.

16:44Now officials say they are in critical condition and they are receiving medical care. So that's the important headline there. Also, we're learning that the suspect is in custody and the suspect was shot in this instance by additional National Guardsmen who were on the scene. Not clear exactly who shot him, but they were able to subdue him after the shooting. The investigators are working on his identity now and looking at any connections that he might have had, but they say this was a single shooter and they believe that there are no other suspects at this time. They say this shooting happened right at the exit to the metro here, just around the corner from the White House, and that the shooter approached the National Guardsman, discharged his weapon immediately, and then almost immediately after that was set upon by the other National Guardsmen who were there.

17:36The Secretary of Defense, Pete Hegseth, Secretary of War, as he refers to himself, is now calling for an additional 500 National Guardsmen to be sent to the District to Colombia to reinforce security here. He says he's doing that at the direction of the president of the United States. So we will see more troops on the streets here in Washington, D.C., Melissa. Back over to you. Eamon, thank you. Eamon Jabbers. Coming up, Oracle off the mat, the bounce in that stock after a rough month and why Wall Street says the tech giant isn't getting the love it deserves. Plus, the dark side of Bitcoin, the crypto heist making headlines and the millions stolen from one tech investor at gunpoint.

18:13The details ahead do not go anywhere. Fast Money is back in tune. This is Fast Money with Melissa Lee, right here on CNBC.

18:28Welcome back to Fast Money. Oracle shares showing signs of life jumping 4 % today as Deutsche Bank reaffirms its buy rating on the cloud company. The firm saying Oracle is getting little credit for its business with OpenAI, which they argue solidifies Oracle's leadership in deploying AI cloud infrastructure at scale. Shares are still down over 37 percent since its peak in September. Tim, would you agree with this assessment on Oracle? I would on valuation, and I would in terms of sentiment. I think it's absolutely overdone because it's starting with the premise that they are ground zero for AI debt concerns, even before they've really created an actual credit profile that should warrant that.

19:08If you look at the historical valuation somewhere here after a from that September 10 closing high, so not even the intraday high to even where it's now rallied back, it's still down 35 percent. It puts 26 multiple of EBIT somewhere around 22, 23, maybe even a bit lower. And that is in line with historical. So I just you know, I don't love Oracle. I don't love this. Let's put it this way. The strategy has been so much so fast and it has been extraordinary. It's hard to like the price action, which has been extremely volatile in both directions. Having said that now, after you've kind of round tripped a lot of that, I think the valuation makes sense.

19:49And those numbers, those multiples on 26 and even 27 are numbers before the open AI ingredients into top line and bottom line. So I kind of like the call. It feels like now Oracle's like a battleground stock, right? I mean, it's back to June levels, basically. So as Tim had mentioned, no open AI deals priced into the valuation here. DA Davidson yesterday said, you know what, if you take a look at the CDS, it's rising. And they don't believe in a default, but they're just saying the market is realizing that what is being priced in is this notion that maybe Oracle, that they're based there depending on spend that's going to happen from a customer that may or may not actually see the returns.

20:30Yeah. May not be there ultimately. I went back and watched all the September 10th videos, read a bunch of stories, and people were tripping over themselves to say. And I think we talked about it either that night or a couple nights later. It didn't make a lot of sense to us, excuse me, collectively, just because the revenue is fine. But we didn't know what the earnings were in the back of it. Now, subsequently, I never thought we'd back and fill to levels. We got to here we are. I don't think it was meant to be at three hundred and twenty something dollars. I don't think it should have traded below 200.

20:59It'll sort of sift in. Tim is right. Valuation, you can get your arms around. And prior to this, this was sort of a slow and steady old tech play that was working. Now they put a bullseye on their back, whether they realize it or not. If you look back to those June levels gapped up from one 70s up to two 15 or so, I would look at this week's lows somewhere around one 94. four. Use that as your stopout if you have to be long the stock. But I think it bounces further. By the way, the Deutsche Bank analyst,$375 price target on this one, Mike. Yeah, not for me. Look, I mean, if you're concerned about the trade in the AI space in general and you're trying to look for kind of a long and a short, I just don't understand why you wouldn't continue to be long a name like Alphabet and potentially on the short side an Oracle.

21:47It's still trading a turn or two above its long-term average. It has negative free cash flow. It's, you know, it's not one of the ones that I would pick to continue into that trade. If anything, it would be the opposite side of the ones that I like in this space. Coming up, the dark side of the crypto trade. How a recent crypto heist is putting the safety of self-storage into focus and the impact it could have on Bitcoin prices. You're watching Fast Money Live from the Nasdaq Market Side in Times Square back right after this.

22:22Welcome back to Fast Money, a dark side of the crypto trade coming into focus after a targeted heist left one tech investor robbed of$11 million worth of Bitcoin and Ethereum. Mackenzie Sigal has got the details on this one. Mackenzie. Hey, Melissa. So Y Combinator CEO Gary Tan, a friend of the victim, posted security footage showing someone posing as a delivery man rushing into a San Francisco home in broad daylight. Now, police say the intruder tied up the resident, demanded access to his financial accounts, and then stole about$11 million worth of crypto using the digital keys that were stored on the victim's laptop and phone.

22:57And inside the industry, these are known as wrench attacks, where criminals have realized that it's often easier to show up with a weapon than hack a wallet online. Facial recognition, that makes it even simpler. You tie a victim up, point the phone at their face, and then drain their account. Based on public reports, there have been more than 60 of these physical attacks on digital asset investors so far this year. NBC News has identified crypto-related kidnappings in 44 countries, including brutal cases in France and a high-profile abduction and torture of a trader in a Manhattan townhouse last year.

23:28I will say this, we tend to see upticks during market surges like last November as Bitcoin hit a new record high after the election and in tandem with the run-up we saw last month. Mel? Wow. Mackenzie, thank you. Mackenzie Sigalos. This happens, obviously, if it's self-storage, self-custody. But I guess in theory, with facial recognition, you can also access a Coinbase account. Which is terrifying. Uh-huh. It is. And that's just the world we live in now, unfortunately. Now, I don't know if you necessarily want to trade around this, but one, it's a horrible thing. Two, I think it's very encouraging that Bitcoin got off the mat the way it did, because we were precariously close to trading at the level that is, to me, concerning.

Read the full transcript

24:09And that sort of coincides with where strategy's average price is, which is now, I think, north of$75 ,000, and where Bitcoin actually got down to. I don't know what happens if and when, but clearly now it's on everybody's radar screen because more and more people are starting to write about it. And this is what we were talking about before. ETFs for the average person who wants crypto exposure is probably the easiest way to gain that exposure because whether it's cold storage, whether it's self-storage, whether it's hot storage, it gets really confusing for the average investor. So I guess other than not telling people how much you own and being off the grid someplace, there's really no way to protect against a crazy person doing this, right?

24:50Yeah. In terms of just the price action of Bitcoin, I mean, Tim, you've made the point many times that this is a time when there is probably the most institutional investor, the most diversified holder base, And yet we're seeing this huge downshift, I guess, in the trade. Right. And the most regulation around it and probably the least amount of these events. I mean, I understand this is an awful, awful event and safety around self-storage is a clearly a big issue. But is it a bigger issue today than it was five years ago or 10 years ago? I think not. I think all of these issues are more publicized because Bitcoin is an asset class that everybody's following.

25:30I, you know, look, this level to buy this dip on Bitcoin is something that's going to look very obvious in the rearview mirror whenever that is. And for people that own Bitcoin, yes, there are a portion of them are trading it. But most of the new investors that have come in, especially on the institutional side, my senses and certainly a lot of the retail, especially the advisory community that's recommending these ETFs, they're not running for cover after a 15 percent pullback. And if they are, they shouldn't have been here. Tomorrow is what day? Gobble, gobble. It is. Turkey Day. And, Mike, I don't know what you discussed during Thanksgiving.

26:05Bitcoin often comes up when you're in the midst of sort of an uptrend in the trade. That is the talk. Who has owned Bitcoin for the past couple of years? Because they are geniuses, right? And they are wealthy now. Yeah. I mean, look, I think that the I actually thought we might have tested those April lows in Bitcoin. But I think that names like strategy look quite appealing here now that basically the bloom is off the rose. and consequently it's not trading at a premium any longer. Fully diluted, I think maybe there's about$3.5 billion. So if you take the market cap of strategy, add$3.5 billion to it, and then figure out what the price of the$650 ,000 Bitcoin that they hold relative to that number is.

26:44And I think you get to see that you have sort of a positive convexity if you're long strategy relative to Bitcoin. Could we see more volatility? Could it test those April lows? I suppose it could. I think there's a lot of people who are shooting against their cost basis. They're shooting against that lower fib and they're shooting against the April low. But I think that you're probably going to be happy if you buy either Bitcoin or strategy here looking out, you know, a year or more. Coming up, your favorite game with a holiday twist. A Thanksgiving Day edition of Traded or Faded with some of this year's biggest winners and losers where our gang says they see those names heading into year end when Fast Money returns.

27:22Missed a moment of fast? Catch us anytime on the go. Follow the Fast Money Podcast. We're back right after this.

27:34Welcome back to Fast Money. Stocks notching a fourth straight day of gains ahead of the Thanksgiving break. The Dow jumping more than 300 points. The S &P up nearly seven-tenths of a percent. And the Nasdaq leading the gains up eight-tenths of a percent. On pace for its best week since May. And some stocks hitting fresh all-time highs. Insurance names like Lowe's and travelers. GM touching its best level since its post-financial crisis IPO. And Walmart of 2%, also hitting new highs ahead of Black Friday. Meantime, before we sit down for our Thanksgiving feast, we thought it'd be a good time to revisit some of the stocks we're thankful for.

28:06And maybe others that could be turkeys. Not to be mean to turkeys. So why not play America's favorite game, trade it or fade it, Thanksgiving edition. First up, Boeing, the top percentage gainer in the Dow today at more than 2%. The aerospace company now 6 % higher this year. Steve, are you thankful for Boeing or is it going to be a turkey? I am thankful for Boeing. I am long Boeing and I'm looking forward to a return to consistent free cash flow, ramping production on the 737 MAX, 777, 787, all of the hosts of their fleet. It's been a tough go for Boeing, but they are a duopoly. And if you if you look at it through that prism, I think that there will be higher prices going forward.

28:53What do you say, Mike? I would have to say I think this one's a little bit of a turkey. I'm gonna fade Boeing here. Look, I mean the valuation on an price value basis is about where it was in 2018 at a period of time, by the way, when the company was making over nine billion dollars in net adjusted income and had significant free cash flow, which it doesn't have now. It doesn't have anywhere near that kind of net income. and the balance sheet is a little bit more wobbly than it was. So I'm glad to see it's going up. Great American industrial company, but I'm not a buyer. Next up on the plate, gold.

29:29The commodity in the green today, just 5 % away from last month's all-time highs. It is up 58 % this year. Guy, I'm going to read what's at the bottom of the screen. Please read it. Thank it or turkey it? Is that what that said? I don't think that's not English. Thank it? There are young people out there. It doesn't mean anything. Thank it or turkey it. Is it a turkey or are you thankful for it? Thank it or tank it. Or turkey it. But we have to keep Thanksgiving. That's a good section point by you. Anyway. Given those rules, I will thank it. Makes no sense. Is there a little, do I get the graphic or drop?

30:04No? I didn't hear any. I didn't hear any. You're thanking it. It says fade it. Gold, I'm not. I'm very confused. I'm not fade. Never. How can you never? They know this. No, the big one on the bottom supersedes the small. Yes, the big one. You wrote on a cave wall. And a cave wall with, like, Fred Flintstone with, like, the chisel. No, I think, listen, the gold trade is alive and well. You do not fade gold, in my opinion. Gobble, gobble, thank it. Whatever you want to say, play the music. I still like it. How about you, Steve? I'm bird or bust. I go bird on this. That means you like it. Nobody's playing the game.

30:43I trade it. I trade it. I like it. I think that whether it's gold or whether it's Bitcoin or whether it's Ethereum or crypto, I think you need an alternate investment. And I think with rate cuts coming, you want to be in one of those three. This is the problem with a lot of the games that we have a lot of games problems. Sometimes you get into the game, you don't even know what you're saying. I mean, it's meaningless. Thank it or turkey it. And then they play the turkey for anything. I mean, whatever. OK. United Health, the stock under the weather, slipping more than 35 percent this year. the sector facing a tough year.

31:14So, Tim, do you trade it or fade it? Let's go old school. Trade it or fade it? You can't change. I'm going to thank it. I'm going to. OK, it's not a turkey. Don't play the turkey sound. It's the Thanksgiving edition. You can't talk about. I mean, come on. Yes. I mean, look, you should be thankful that I'm taking the two hardest stocks in this game tonight because this isn't easy. But I'm thankful and I'm certainly not going to trade it. I think it's a case where we've gotten enough updates in terms of Medicare Advantage. We have some insight into 26. This is, again, a valuation story. Once you got past any concern that the F word, and I mean fraud was being thrown around, this is a story more on margin and where this company sits.

31:55I'm thankful I didn't own it from 600 down to 300 or 240. And I do own it today. And I expect to be thankful a year from now that I bought it. Mike Coe? Trade it. Thankful. Whichever other way we're supposed to describe it. I'll do both. I like UnitedHealth here. Look, I think Tim's right. We put the worst of it behind us, one hopes. The valuation is very attractive. This actually has been a great performer for at least 15 years as a company, barring that little period when we had different management. We're back to the previous management now, and I think we're going to get this company back on track.

32:30I like it here. All right. I like how they just play the turkey sound, no matter what you say. This is the greatest sound ever. Is that a human? No, it's a turkey. It's a real turkey. But a human made the sound. Hired a turkey. It's actually Maurice. Maurice is a man of many talents. He's very talented, obviously. I mean, that turkey is very convincing. That might be him in IRL right now. It's not even a drop. You never know. Coming up, sizing up the weight loss trade. We'll debate whether Lilly shares can hold on to their lead over competitors and the next generation drugs to watch. Back right after this.

33:11Welcome back to Fast Money. It's been a blockbuster year for Eli Lilly, now up 43 % since January, while obesity drug rival Novo Nordisk has fallen by about the same amount. But attention is shifting to new competitors in the space, with Amgen set to release some new data on its monthly obesity shot before year-end. Our next guest says potentially strong data could put pressure on Lilly shares. For more, let's bring in Kessif Capital Managing Director Len Yaffe.

33:38Len, great expecting a couple of readouts on Maritide, Amgen's drug lens. So what's the scenario here? The data is good and what do you characterize as good and what does that mean? I think the key with Maritide, and this is part two of a phase two study, is what is the incidence, if we learn, of nausea and vomiting? The issue surrounding Maritide isn't so much the efficacy, but it's the side effect issue. And if we get some understanding of that, that could either make people feel more comfortable with the drug or make it less likely that the drug would be significant. My bigger concern with Maritide is that it's not slated to get FDA approval until 28 or 29.

34:26By then, Lily will have three drugs on the market for obesity and four drugs in advanced clinical study. Novo, which I've just recently started to accumulate, will have three drugs on the market and at least one significant drug in advanced clinical study. So I think that even though Maritide could be very promising as a once-a-month drug, which would be in advance over the weekly drugs that we have now, and possibly even now to once every three months, given the doses they're studying, the time when it's coming to market may leave it very little market share to gain. So basically, the note that you shot out a couple of weeks ago that caught my eyes is the premise that if the Maritai data were good by the end of the year, that you could see Lilly take a hit and Amgen gain.

35:16But that sounds like it's a very short term sort of phenomenon in that longer term Lilly could still be in the driver's and potentially Novo could be the value play here. Exactly. I totally agree. You know, Lily, as you mentioned at the start, has gone up very significantly. When I established a price target three years ago, it was$1 ,100. And so it's there. And I'm very thankful for that. But it's going to be hard to get Lily to move significantly higher from here in the short term. It might take time for estimates to increase and then to look out in later years earnings for the stock to go up.

35:58So my concern was if Maritide had favorable data associated with it, people at this valuation may look to take profits in Lilly, which has just been outstanding. All right, Len, I know we talk about Lilly all the time. Amazing company. Trades at almost 35 times next year's numbers. They deserve a premium. But you're talking about them at 35 times Bristol, Merck, 11, maybe 12 times. And I get there should be a disparity. But at what point is valuation a concern? Great question. And my estimate for next year is thirty five dollars per share. So it's about thirty one times my estimate. And I talked with you folk several months ago that I felt were undergoing a pharmaceutical research renaissance.

36:48at a time when valuations were very low. And so that disparity needed to get resolved. It did with the stocks going up. So your point is well taken that Merck has 30 drugs in phase three. People, I think, underestimate its oncology pipeline. It is not going to be a significant player in obesity. Same with Bristol. So we're looking at a drug category this year that's going to be$20 billion in the U.S., going to, in my opinion,$150 billion by 2030. Those companies have great pipelines in other areas that are doing well, but not in this category that I've called the most transformative drug class of my career.

37:33And the reason, importantly, is not obesity per se. It's because these drugs, the incretins and the amylins, help prevent the morbidity, mortality, aid and costs associated with seven of the most common chronic conditions in the U.S. And I'll just add that ICER, the Institute for Clinical Economic Research, a very highly regarded group that analyzes drug costs, just had a symposium two weeks ago where they said that ZepBound, which is much better than McGovie, at its lower price that was recently proposed by President Trump, in addition to lifestyle management, was not only better than lifestyle management alone, but it was cost savings.

38:22So it's not just a better quality of life, a longer life, but unlike any other category of drug I can think of, it actually saves the system money. I think that this drug category is tremendous. Len, great to speak with you. Thank you. Happy Thanksgiving. Have a great holiday. Len Yaffe, you mentioned the valuation of Lilly being rich. What did you say,$39,$38? $34. So he's anticipating$35, so his valuation is a little cheaper. I had it at$32, but yes. Walmart is north of$40. Yes. Why shouldn't he like Lilly? I mean, I know that's apples and oranges, but. No, it's fair. Look, it's fair. I just I think at some point in health care, given the despair.

39:07And, you know, it's funny. It's not that difference between Walmart and Target as opposed to Eli Lilly and Merck or Bristol Myers. The difference is I think Merck and Bristol are in a much better position than Target is vis-a-vis Walmart. Mike, what do you say? We own Lilly. It's about a four percent allocation in the portfolio. So obviously I like it. It has had quite a run here, though. So we've actually been selling some upside calls against this one. collect a little bit of extra premium going into the end of the year. But I mean, when you take a look at the growth rates, and that's both top and bottom line, because they're probably going to have 18 % revenue growth year on year, and 35, 36 % anyway, year on year on the adjusted EPS side.

39:46So it's not expensive. Coming up, we're flying into airline stocks as millions of Americans hit the skies for the Thanksgiving weekend. How the weather could impact your travel plans and the names that could gain some altitude. More Fast Money in two.

40:04Welcome back to Fast Money. Airlines kicking into high gear. Cities across the country are experiencing severe weather heading into the holidays. AAA projects 6 million U.S. travelers to take domestic flights over the Thanksgiving holiday period. That's a 2 percent increase from last year. Airline stocks lifting off with American and Delta Airlines leading the group. Tim, we were talking about this yesterday in terms of sort of the consumer-facing names getting a lift, and the airline stocks are among them. And they're continuing to spend on airfare. And Delta Airlines is continuing to draw also premium cabin, whether it is corporate and business class or whether it's even some of the features in kind of the main plus or premium economy.

40:46What it translates to is not only 10 percent sales growth, which is significant, but that it's a higher margin business that's also feeding through to the multiple of the company, which trades at multiples from five years ago. It's a much more valuable company because it's a much more efficient company and it is best in class. And the noise around the FAA cancellations was just that. I think there is strong carryover from third quarter demand into the fourth quarter. I don't think we've seen airline traffic pullback with the same kind of concern other parts of the consumer spectrum is. So no secret, I'm long Delta.

41:21I think this is a great opportunity. I think it's going to all time highs in the next couple of months. You know, when you look at Delta, everyone always throws in United into that class. I think Delta's chart, Tim laid out why the premium, the front of the plane has been selling, and those help the margins. International's coming back. Corporate travel is there, which is a premium margin on that. But when you look at United, the chart doesn't look as good to me as when you look at Delta. So Tim talked about fundamentals. Technicals are really a tell went to Delta as well. $70 was the all time, a little less than$70 back in February.

41:55And I like the planes where you stare and there's nothing in front of you. Well, you wear a tie. No screen. You're all dressed up. Nothing. What do you call that? Loosen to tie. It's called raw dogging. And you just stare. But you quickly fall asleep. Let's be clear. It's not like you're awake staring for a long period of time. Maybe it's like medium rare dogging. Up next, Final Traits.

42:20Final Traits, Tim. First of all, thankful for you there on the desk. Thankful to everybody at home. And thankful for Delta Airlines. Happy Thanksgiving. Michael Coe. Yeah, American Express has had a good year. I think next year will be even better. I like AXP. C. A stock that has not performed. A stock that has not performed, but I'm looking for it to bounce back. Pfizer. Thank you for that turkey sound. I'm not. Have fun tomorrow. I am thankful for this show, everybody on it. You especially, Melissa Lee, and the crack staff back in EC and all the folks that watch. Happy Thanksgiving. Harmony Gold.

42:57Have a safe one. We'll see you back here on Monday. Thank you for watching Fast. Mad Money starts right now.

43:07All opinions expressed by the Fast Money participants are solely their opinions and do not reflect the opinions of CNBC, NBC Universal, their parent company or affiliates, and may have been previously disseminated by them on television, radio, internet, or another medium. You should not treat any opinion expressed on this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion. Such opinions are based upon information the Fast Money participants consider reliable, but neither CNBC nor its affiliates and or subsidiaries warrant its completeness or accuracy, and it should not be relied upon as such.

43:41To view the full Fast Money disclaimer, please visit CNBC.com forward slash Fast Money disclaimer.

From the publisher

Listen to our traders take you behind the money...how to play the volatility...pops and drops and the movers you missed.

Fast Money Disclaimer


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

More from CNBC's "Fast Money"

All 871 episodes
Fast Money 11/26/25CNBC's "Fast Money" · 44 min
Listen in VO